- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05287009
Optical Coherence Tomography Angiography (OCTA) Changes in Patients With Epiretinal Membranes (ERM) With and Without Peeling of the Internal Limiting Membrane (ILM)
Optical Coherence Tomography Angiography (AngioVueTM, Optovue Inc., Fremont, Calif., USA) Changes in Patients With Epiretinal Membranes (ERM) With and Without Peeling of the Internal Limiting Membrane (ILM) - a Pilot Study
Main objective
The objective is to compare two surgical options in vitrectomies for epiretinal membranes using parameters of optical coherence tomography angiography.
Background
State of the art treatment for epiretinal membranes consists of pars plana vitrectomy, staining of the epiretinal membrane with a blue colouring dye and epiretinal membrane peeling. The vitrectomized space is filled with fluid (balanced salt solution) during the procedure and the fluid can optionally be replaced with air as a final step. After ERM peeling (but before the selection of the tamponade), the internal limiting membrane (the innermost layer of the retina) is either peeled as well or left untouched and the question which method should be preferred has been a hot topic in recent years. The investigators want to investigate possible effects of the used method (peeling vs. nonpeeling) on retinal perfusion parameters represented by OCTA. Two epiretinal membrane patient groups will therefore be formed: The first group's (group 1) ILM will be peeled, the second group's (group 2) ILM will not be peeled. After recruitement, patients will therefore be electronically randomized to one of the two groups. The groups will then be compared by the means of OCTA.
Study design
- Since there are no previous data on our research question, this investigation is defined as a pilot study.
- 40 patients with epiretinal membranes will be included. This appears to be a reasonable number given the incidence of epiretinal membranes. Previous studies that compared peeling versus nonpeeling in ERM used similar sample sizes. The detectable effect size was calculated at d = 0.91. We intend to complete this pilot study within 9 months.
- Randomization will be performed using electronic randomization. 20 patients each will be randomized to either group 1 or group 2.
- Both eyes in each patient will be imaged.
- No treatment decisions will be made based on OCTA findings. Treatment decisions will be made according to the clinic's standard of care.
- Three follow-up visits specific to the study are needed. These visits will be scheduled one week, one month and three months after surgery. All other preoperative and follow-up visits will be decided by the treating physician and follow the clinic standard of care.
Examinations
- Distance visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) standard at 4 meters as per clinic standard of care.
- Tonometry as per clinic standard of care.
- Slit-lamp evaluation as per clinic standard of care.
- Arterial blood pressure.
- Axial eye length.
- Heidelberg Spectralis conventional OCT.
- The following 2 AngioVue scans will be taken:
A. One 3mm x 3mm, 304 x 304 A-scan OCTA of the macula B. One 6mm x 6mm, 304 x 304 A-scan OCTA of the macula
Hypothesis
The null hypothesis of our investigation indicates that there are no statistically significant differences in OCTA perfusion parameters based on the used option.
The alternative hypothesis states that there are statistically significant differences in OCTA perfusion parameters based on the used option.
Primary Objective
To demonstrate possible differences in OCTA perfusion parameters based on the used option.
Secondary Objectives
To assess the feasibility of the AngioVue optical coherence tomography angiography system in evaluating subtle changes in the retinal perfusion of patients with epiretinal membranes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Styria
-
Graz, Styria, Austria, 8010
- Medical University Graz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must be able and willing to give informed consent.
- Patient must be over 18 and below 100 years of age.
- Patient must not have any significant media opacity which interferes with the examination.
- Patient must have an epiretinal membrane requiring surgery.
Exclusion Criteria:
- Unwilling or unable to provide informed consent
- Under 18 or over 100 years of age
- Significant media opacities
- Systemic pathologies making an examination difficult or cumbersome to the patient
- Secondary epiretinal membranes
- Bilateral epiretinal membranes
- Macular holes
- Lamellar holes
- Pseudo holes
- Glaucoma
- Diabetes
- Anisometropia > 2 diopters
- High myopia (spherical equivalent > 6 diopters and/or axial length > 26 mm
- Other retinal or ophthalmic pathologies except moderate cataract
- OCTA scan signal strength < 50
- Low image quality
- Failure of automatic layer segmentation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ILM nonpeeling
|
ILM is not peeled after ERM removal
|
|
Other: ILM peeling
|
ILM is peeled after ERM removal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Superficial capillary plexus foveal avascular zone area
Time Frame: 3 months
|
Superficial capillary plexus foveal avascular zone area (SCP FAZ) change (preoperative to postoperative).
The SCP FAZ represents the area of the macula where blood vessels are not seen in OCTA under physiologic conditions.
It has previously been reported that the FAZ narrows during ERM development and enlarges after ERM removal.
|
3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 32-443 ex 19/20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epiretinal Membrane of Both Eyes
-
Tanta UniversityCompletedRhegmatogenous Retinal Detachment of Both Eyes (Diagnosis)Egypt
-
Universiti Sains MalaysiaRecruitingAllergic Conjunctivitis of Both Eyes | Dry Eye SymptomsMalaysia
-
Instituto de Oftalmología Fundación Conde de ValencianaInstituto de Oftalmología Fundación Conde de ValencianaActive, not recruitingAllergic Conjunctivitis of Both EyesMexico
-
Farabi Eye HospitalUnknownKeratitis of Both Eyes
-
Duke UniversityCompletedMaculopathy | Hypotony Ocular | Cornea Folds and Rupture of Bowman's Membrane Both EyesUnited States
-
Asociación para Evitar la Ceguera en MéxicoRecruitingEpiretinal Membrane SurgeryMexico
-
Assiut UniversityNot yet recruitingPterygium | Pterygium of Conjunctiva and Cornea | Pterygium of Both EyesEgypt
-
Centre Hospitalier Universitaire DijonTerminatedEpiretinal Membrane SurgeryFrance
-
Instituto de Oftalmología Fundación Conde de ValencianaCompleted
-
Ohio State UniversityAlcon ResearchCompletedContact Lens | Astigmatism of Both EyesUnited States
Clinical Trials on ILM nonpeeling
-
Vienna Institute for Research in Ocular SurgeryCompleted
-
Xinhua Hospital, Shanghai Jiao Tong University...Recruiting
-
Rush Eye AssociatesActive, not recruitingDiabetic Retinopathy Visually ThreateningMexico
-
Sohag UniversityRecruiting
-
Federal University of São PauloUnknown
-
Changhua Christian HospitalCompletedRetinal DetachmentTaiwan
-
Military Institute of Medicine, PolandUnknown
-
Vienna Institute for Research in Ocular SurgeryCompleted
-
Wenzhou Medical UniversityUnknown
-
Xinhua Hospital, Shanghai Jiao Tong University...Shanghai Municipal Science and Technology CommissionRecruiting